Drug & intervention

lamotrigine

RxCUI 28439

Clinical trials15
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Lamotrigine

Lamotrigine ( luh-MOH-trih-jeen), sold under the brand name Lamictal among others, is a medication used to treat epilepsy and stabilize mood in bipolar disorder. For epilepsy, this includes focal seizures, tonic-clonic seizures, and seizures in Lennox-Gastaut syndrome. In bipolar disorder, lamotrigine has not been shown to reliably treat acute depression in any groups except for the severely depressed; but for patients with bipolar disorder who are not currently symptomatic, it appears to reduce the risk of future episodes of depression. Lamotrigine is also used off label for unipolar depression (major depressive disorder), treatment-resistant obsessive-compulsive disorder, and depersonalization-derealization disorder. Common side effects include nausea, sleepiness, headache, vomiting, trouble with coordination, and rash. Serious side effects include excessive breakdown of red blood cells, increased risk of suicide, severe skin reaction (Stevens–Johnson syndrome), and allergic reactions, which can be fatal. Lamotrigine is a phenyltriazine, making it chemically different from other anticonvulsants. Its mechanism of action is not clear, but it appears to inhibit release of excitatory neurotransmitters via voltage-sensitive sodium channels and voltage-gated calcium channels in neurons. Lamotrigine was first marketed in Ireland in 1991, and approved for use in the United States in 1994. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the most commonly prescribed mood stabilizer and 59th most commonly prescribed medication in the United S...

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

15 shown
Bariatric Surgery and Pharmacokinetics of LamotrigineNCT03497143 · 2016-11-02
RECRUITING
Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01
TERMINATED
PET and MRI Brain Imaging of Bipolar DisorderNCT01880957 · 2011-11-08
COMPLETED
Treatment of Alcohol Dependence and Comorbid Bipolar DisorderNCT01015586 · 2010-02-01
COMPLETED
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple SclerosisNCT00917839 · 2009-06-01
UNKNOWN
Pharmacokinetic Study on Raltegravir and LamotrigineNCT00618241 · 2008-02-01
COMPLETED
Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II DepressionNCT00475137 · 2007-12-01
COMPLETED
Research Study for Major Depressive Disorder: Investigation of Glutamate MedicationsNCT00419003 · 2006-12-01
COMPLETED
Lamotrigine in the Treatment of Binge Eating Disorder Associated With ObesityNCT00277641 · 2006-03-01
COMPLETED
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple SclerosisNCT00257855 · 2005-11-01
COMPLETED
Study Of An FDA-approved Drug As Additional Therapy In Patients With SchizophreniaNCT00086593 · 2004-05-01
COMPLETED
Lamotrigine Augmentation in Resistant DepressionNCT00901407 · 2003-12-01
COMPLETED
Clinical Study Of Schizophrenia in Both Men and WomenNCT00071747 · 2003-08-01
COMPLETED
Study of Efficacy of Lamotrigine in Therapy of Bronchial AsthmaNCT00153244 · 2002-08-01
COMPLETED
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)NCT00012558 · 1998-09-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.